| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Amonafide (formerly NSC308847, AS1413; AS-1413; NSC-308847; Amonafide; Nafidimide; Benzisoquinolinedione; Quinamed; Xanafide), an imide derivative of naphthalic acid, is an inhibitor of topoisomerase II (Topo II) and also a DNA intercalator being investigated for the treatment of cancer.
| Targets |
Topoisomerase II
|
||
|---|---|---|---|
| ln Vitro |
|
||
| ln Vivo |
|
||
| Cell Assay |
In studies that track survival after one-hour drug treatments, 2 × 106 cells are resuspended in 2 mL of warm (37°C) HBSS with 5% PCS; adding less than 50 μL of the appropriate drug (amonafide) brings the cell count down to the desired level. Ten milliliters of ice-cold PBS are added to the cells after they have been incubated for sixty minutes at 37°C. Next, the cells are centrifuged for 10 minutes at 4°C at 200 × g. To determine the number of surviving clonogenic cells, the cells are washed again, resuspended in HBSS containing 5% PCS, and added to the agar-medium mixture[2].
|
||
| Animal Protocol |
|
||
| References |
|
| Molecular Formula |
C16H17N3O2
|
|---|---|
| Molecular Weight |
283.33
|
| Exact Mass |
283.13
|
| Elemental Analysis |
C, 67.83; H, 6.05; N, 14.83; O, 11.29
|
| CAS # |
69408-81-7
|
| Related CAS # |
:69408-81-7 150091-68-2 (2HCl)618863-54-0 (L-malate) 618863-60-8
|
| Appearance |
Solid powder
|
| SMILES |
CN(C)CCN1C(=O)C2=CC=CC3=CC(=CC(=C32)C1=O)N
|
| InChi Key |
UPALIKSFLSVKIS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H17N3O2/c1-18(2)6-7-19-15(20)12-5-3-4-10-8-11(17)9-13(14(10)12)16(19)21/h3-5,8-9H,6-7,17H2,1-2H3
|
| Chemical Name |
5-amino-2-[2-(dimethylamino)ethyl]benzo[de]isoquinoline-1,3-dione
|
| Synonyms |
AS1413; NSC308847; AS1413; NSC-308847; AS-1413; NSC 308847; AS 1413; Amonafide; Nafidimide; Benzisoquinolinedione; Quinamed; Xanafide
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.82 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (7.34 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5295 mL | 17.6473 mL | 35.2945 mL | |
| 5 mM | 0.7059 mL | 3.5295 mL | 7.0589 mL | |
| 10 mM | 0.3529 mL | 1.7647 mL | 3.5295 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00273884 | Completed | Drug: Amonafide L-Malate Drug: Cytarabine |
Acute Myeloid Leukemia | Xanthus Pharmaceuticals, Inc. | August 2005 | Phase 2 |
| NCT00074100 | Completed | Drug: amonafide dihydrochloride | Breast Cancer | Memorial Sloan Kettering Cancer Center |
August 2003 | Phase 2 |
| NCT00087854 | Completed | Drug: Amonafide L-malate (drug) |
Prostate Cancer | Xanthus Pharmaceuticals, Inc. | March 2004 | Phase 1 Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA